Helix Acquisition Corp. II operates as a blank check company. The company is headquartered in Boston, Massachusetts. The company went IPO on 2024-02-09. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company has entered into a business combination agreement with TheRas, Inc., doing business as BridgeBio Oncology Therapeutics. Upon closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics, Inc.
What is BridgeBio Oncology Therapeutics Inc (BBOT)'s P/E Ratio?
The P/E ratio of BridgeBio Oncology Therapeutics Inc is 109.6758
What is the price performance of BBOT stock?
The current price of BBOT is $8.99, it has increased 1.23% in the last trading day.
What are the primary business themes or industries for BridgeBio Oncology Therapeutics Inc?
BridgeBio Oncology Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is BridgeBio Oncology Therapeutics Inc market cap?
BridgeBio Oncology Therapeutics Inc's current market cap is $719.1M
Is BridgeBio Oncology Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for BridgeBio Oncology Therapeutics Inc, including 3 strong buy, 4 buy, 1 hold, 0 sell, and 3 strong sell